第678回 生医研セミナー(多階層生体防御システム研究拠点)
免疫機構研究セミナー / 九州大学病院ARO次世代医療センターセミナー
下記の通り、Dr.Sznolによるセミナーを開催致します。
皆様の積極的なご参加をお待ちしています
演題
Advances in Immune Therapy of Metastatic Renal Cancer（転移性腎臓がんに対する免疫療法の進歩）
演者
Professor Mario Sznol
Yale University/Smilow Cancer Center, USA
日時
2014年 7月17日（木） 17：00～18：00
場所
九州大学 病院キャンパス内 臨床小講堂2
以下の地図の16番の建物になります。
（http://www.kyushu-u.ac.jp/access/map/hospital/hospital.html）
要旨
Treatment of metastatic renal cancer with VEGFR or mTOR inhibitors improves outcome but all patients eventually develop disease progression. High dose interleukin-2 can produce durable remissions in a small subset of patients with good performance status and normal organ function, and provides proof of concept that immune therapies are active and should be further developed in this disease. Among the targets for immune intervention, immune checkpoints such as CTLA-4 and PD-1 are particularly important because they are expressed by T-cells after activation, and regulate the activation and function of T lymphocytes from the naïve state through differentiation into effector cells. Antibodies blocking CTLA-4 and more recently PD-1 or its ligand PD-L1 have shown promising activity in metastatic renal cell cancer. For PD-1/PD-L1 antagonists, objective response rates in the range of 13-29% have been observed, and some responses are very durable. Objective response rates for the combination of anti-PD1 and anti-CTLA4 exceeded 40% in a phase 1 trial, albeit with increased toxicity. Increased response rates compared to single agent historical controls were also reported recently for combinations of anti-PD1 with VEGFR inhibitors. Although results from phase 3 randomized trials are not yet available, a subset of patients achieve substantial clinical benefit from the immune checkpoint inhibitors. Further improvement in outcomes could be expected from development of other relevant checkpoint inhibitors in mRCC and from combinations of checkpoint inhibitors with each other, or with cytokines or immune co-stimulatory agents.
Dr.Sznolは悪性腫瘍に対する免疫療法を中心に多くの臨床試験を実施されてきております。今回は第12回臨床腫瘍学会シンポジウムに参加のため来福されましたので、九州大学病院でのセミナーもお願いいたしました。本セミナーでは特に最近注目されてきています。免疫チェックポイント阻害抗体療法を用いた臨床試験成果について最新の情報を紹介していただきます。
連絡先
生体防御医学研究所 ゲノム病態学分野
谷 憲三朗
電話：092-642-6434